Our Aim
Artugen strives to identify novel therapies to help patients living with infectious, inflammatory and oncologic diseases.
News & Publications
Artugen is currently enrolling in C. difficile infection study.
Artugen is currently enrolling subjects in “A Randomized, Placebo-Controlled, Double-Blind, Phase 1 Study of ART24 in Subjects Recently Cured of a C. difficile infection” We are looking for volunteers to participate in [...]
Artugen Announces Five Abstracts Published in the 30th ECCMID Abstract Book
The European Congress of Clinical Microbiology and Infectious Diseases happens from 18–21 April in Paris
Artugen Therapeutics Announces First Patient Dosed with ART24
March 12, 2020 Artugen’s first clinical product candidate for prevention of recurrence of Clostridium difficile infection - ART24 granted Fast Track Designation - First Patient Dosed
Tackling the biggest global health threats
Clostridioides difficile infection (CDI) causes the most common healthcare-associated infections in the United States and the most frequent hospital-acquired intestinal infection in Europe and worldwide. The prevalence of C. difficile outbreaks since the early 2000s has resulted in higher morbidity and mortality along with increasing medical costs throughout the world.
Without effective antibiotics and therapeutics for the prevention and treatment of infections, many of the achievements of modern medicine such as organ transplantations, chemotherapy and surgeries such as caesarean sections become much more dangerous.
The Artugen team has discovered and is developing a novel oral Live Biotherapeutic Product for the prevention of C. difficile infection recurrence.